Part B Insider - 2003 Issue 20
CMS Threatens 4 Ways for Oncologists to Suffer - Drugs Could Drop 15 Percent per Year
Subscribe or sign in to view the full article.
Article Overview
This article explains several CMS payment-policy proposals for physician-dispensed drugs and discusses why the changes matter to oncology practices and other providers who bill for drugs under Medicare. It outlines the broad reimbursement methodologies CMS considered, the context behind the rulemaking, and the possibility that pending legislation could affect the outcome. The piece is most relevant to oncologists, administrators, and medical coders following Medicare drug-payment policy.
Why This Topic Matters
Drug reimbursement methodology can materially affect practice revenue, especially for specialties that dispense costly medications. Understanding the policy alternatives and the broader regulatory context helps providers and billing teams anticipate potential payment changes and monitor related federal guidance.
What You Will Learn
- The main CMS drug-payment policy approaches discussed in the proposed rule.
- Why the proposal is significant for oncology and other physician practices.
- How the article situates the CMS rulemaking within broader Medicare and congressional activity.
- The general categories of reimbursement methods CMS considered for physician-dispensed drugs.
Who Should Read This
- Oncologists
- Physician practice administrators
- Medical coders
- Billing and reimbursement professionals
- Healthcare compliance staff
- Payers and policy analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com